These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 12415193)

  • 1. Preclinical development of a vaccine 'against smoking'.
    Cerny EH; Lévy R; Mauel J; Mpandi M; Mutter M; Henzelin-Nkubana C; Patiny L; Tuchscherer G; Cerny T
    Onkologie; 2002 Oct; 25(5):406-11. PubMed ID: 12415193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-nicotine vaccination: where are we?
    Cerny T
    Recent Results Cancer Res; 2005; 166():167-75. PubMed ID: 15648190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity.
    Maurer P; Jennings GT; Willers J; Rohner F; Lindman Y; Roubicek K; Renner WA; Müller P; Bachmann MF
    Eur J Immunol; 2005 Jul; 35(7):2031-40. PubMed ID: 15971275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intranasal administration of recombinant Neisseria gonorrhoeae transferrin binding proteins A and B conjugated to the cholera toxin B subunit induces systemic and vaginal antibodies in mice.
    Price GA; Russell MW; Cornelissen CN
    Infect Immun; 2005 Jul; 73(7):3945-53. PubMed ID: 15972481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Expecting the antinicotine vaccine].
    Didilescu C
    Pneumologia; 2009; 58(3):177-8. PubMed ID: 19817315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
    Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The immunogenicity and safety of a nicotine vaccine in smokers and nonsmokers: results of a randomized, placebo-controlled phase 1/2 trial.
    Wagena EJ; de Vos A; Horwith G; van Schayck CP
    Nicotine Tob Res; 2008 Jan; 10(1):213-8. PubMed ID: 18188762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of oral killed whole cell recombinant B subunit cholera vaccine in Barranquilla, Colombia.
    Concha A; Giraldo A; Castañeda E; Martínez M; de la Hoz F; Rivas F; Depetris A; Svennerholm AM; Sack DA
    Bull Pan Am Health Organ; 1995 Dec; 29(4):312-21. PubMed ID: 8605522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination against nicotine: an emerging therapy for tobacco dependence.
    Maurer P; Bachmann MF
    Expert Opin Investig Drugs; 2007 Nov; 16(11):1775-83. PubMed ID: 17970637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [New prospects of nicotine dependence treatment--vaccines].
    Goniewicz ML; Koszowski B; Czogała J; Zymełka A
    Przegl Lek; 2006; 63(10):1114-8. PubMed ID: 17288232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-nicotine abuse vaccines in the pipeline: an update.
    Cerny EH; Cerny T
    Expert Opin Investig Drugs; 2008 May; 17(5):691-6. PubMed ID: 18447595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Construction and preclinical evaluation of recombinant Peru-15 expressing high levels of the cholera toxin B subunit as a vaccine against enterotoxigenic Escherichia coli.
    Roland KL; Cloninger C; Kochi SK; Thomas LJ; Tinge SA; Rouskey C; Killeen KP
    Vaccine; 2007 Dec; 25(51):8574-84. PubMed ID: 18045752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cholera toxin B stimulates systemic neutralizing antibodies after intranasal co-immunization with measles virus.
    Muller CP; Beauverger P; Schneider F; Jung G; Brons NH
    J Gen Virol; 1995 Jun; 76 ( Pt 6)():1371-80. PubMed ID: 7782766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Probing the protective effects of a conformationally constrained nicotine vaccine.
    Moreno AY; Azar MR; Koob GF; Janda KD
    Vaccine; 2012 Oct; 30(47):6665-70. PubMed ID: 22963803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of a nicotine conjugate vaccine in current smokers.
    Hatsukami DK; Rennard S; Jorenby D; Fiore M; Koopmeiners J; de Vos A; Horwith G; Pentel PR
    Clin Pharmacol Ther; 2005 Nov; 78(5):456-67. PubMed ID: 16321612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nicotine conjugate vaccine as a novel approach to smoking cessation.
    Ottney AR
    Pharmacotherapy; 2011 Jul; 31(7):703-13. PubMed ID: 21923458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic vaccines for nicotine dependence.
    Maurer P; Bachmann MF
    Curr Opin Mol Ther; 2006 Feb; 8(1):11-6. PubMed ID: 16506520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suppression of nicotine-induced pathophysiology by an adenovirus hexon-based antinicotine vaccine.
    Rosenberg JB; De BP; Hicks MJ; Janda KD; Kaminsky SM; Worgall S; Crystal RG
    Hum Gene Ther; 2013 Jun; 24(6):595-603. PubMed ID: 23611296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Recent progress in vaccines against nicotine addiction].
    Wang GB; Zhu CJ
    Yao Xue Xue Bao; 2013 Aug; 48(8):1189-94. PubMed ID: 24187824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of systemic antifimbria and antitoxin antibody responses in Egyptian children and adults by an oral, killed enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine.
    Hall ER; Wierzba TF; Ahrén C; Rao MR; Bassily S; Francis W; Girgis FY; Safwat M; Lee YJ; Svennerholm AM; Clemens JD; Savarino SJ
    Infect Immun; 2001 May; 69(5):2853-7. PubMed ID: 11292698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.